Neonatal screening for XXXX .

@entity1 @entity1032 @entity25248 @entity6750 @entity16 @entity814 @entity774 @entity209 @entity1624 @entity4903 @entity2246
The impact of @entity209 ( @entity2246 ) and @entity4903 in pediatrics has markedly increased during the last few decades. Critical periods in the development of the central nervous system need special attention in @entity1 with these disorders. Early diagnosis and treatment are important in order to prevent @entity1032 and serious handicaps in some of these @entity1 . Certain @entity1 with @entity209 lack early clinical symptoms or have so non-specific signs that permanent @entity16 are present when the @entity1 are finally diagnosed. One way to identify these @entity1 is by means of mass screening. A blood sample is then collected from every newborn @entity1 and analyzed for abnormal levels of metabolites or hormones. It is possible to detect at least thirty different disorders in this way. In most European countries screening programmes involve @entity814 ( @entity814 ) and @entity6750 . The prognosis for these @entity1 has improved dramatically after the introduction of screening. The Swedish neonatal metabolic screening programme was started in 1965 by screening for @entity814 . Subsequently, screening for @entity1624 and @entity6750 was added. The result of the screening programme 1965-1985 is as follows: (table; see text) The main benefit of early detection and treatment of @entity1 with @entity814 , @entity6750 and @entity1624 is the prevention of @entity1032 and other handicaps. Recently nationwide pilot screening for @entity774 ( @entity25248 ) was started.
